Tags

Type your tag names separated by a space and hit enter

Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Am J Cardiol 2009; 104(4):548-53AJ

Abstract

Guidelines have recommended non-high-density lipoprotein (non-HDL) cholesterol as a secondary target for therapy after the low-density lipoprotein (LDL) cholesterol goals have been met in patients with hypertriglyceridemia; non-HDL cholesterol is viewed as a surrogate for apolipoprotein (Apo)B, an alternate end point of treatment. The present analysis of the previously reported Simvastatin plus Fenofibrate for Combined Hyperlipidemia (SAFARI) trial assessed the associations of non-HDL cholesterol and LDL cholesterol with ApoB levels in patients with combined hyperlipidemia treated with combination simvastatin (20 mg) and fenofibrate (160 mg) or simvastatin monotherapy (20 mg). The correlations of these factors were analyzed in the overall modified intent-to-treat population (n = 594) and in patient subgroups stratified by triglyceride (TG) tertiles. Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. The greatest reductions occurred with combination treatment. The baseline levels of non-HDL cholesterol and LDL cholesterol correlated highly with ApoB and were stronger in the lower TG tertiles than in the higher TG tertiles. After 12 weeks, the correlations had changed little with simvastatin monotherapy but had increased substantially with combination therapy and were most improved at high TG levels. In conclusion, these results suggest that both non-HDL cholesterol and ApoB provide similar information in relation to treatment response in patients with combined hyperlipidemia and hypertriglyceridemia, and that non-HDL cholesterol is a good indicator of ApoB-containing lipoproteins, supporting its recommended use as a secondary therapeutic target in these patients.

Authors+Show Affiliations

University of Texas Southwestern Medical Center, Dallas, Texas, USA. Scott.Grundy@utsouthwestern.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

19660610

Citation

Grundy, Scott M., et al. "Correlation of Non-high-density Lipoprotein Cholesterol and Low-density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (a Subanalysis of the SAFARI Trial)." The American Journal of Cardiology, vol. 104, no. 4, 2009, pp. 548-53.
Grundy SM, Vega GL, Tomassini JE, et al. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol. 2009;104(4):548-53.
Grundy, S. M., Vega, G. L., Tomassini, J. E., & Tershakovec, A. M. (2009). Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). The American Journal of Cardiology, 104(4), pp. 548-53. doi:10.1016/j.amjcard.2009.04.018.
Grundy SM, et al. Correlation of Non-high-density Lipoprotein Cholesterol and Low-density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (a Subanalysis of the SAFARI Trial). Am J Cardiol. 2009 Aug 15;104(4):548-53. PubMed PMID: 19660610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). AU - Grundy,Scott M, AU - Vega,Gloria Lena, AU - Tomassini,Joanne E, AU - Tershakovec,Andrew M, PY - 2008/12/23/received PY - 2009/04/08/revised PY - 2009/04/08/accepted PY - 2009/8/8/entrez PY - 2009/8/8/pubmed PY - 2009/8/28/medline SP - 548 EP - 53 JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 104 IS - 4 N2 - Guidelines have recommended non-high-density lipoprotein (non-HDL) cholesterol as a secondary target for therapy after the low-density lipoprotein (LDL) cholesterol goals have been met in patients with hypertriglyceridemia; non-HDL cholesterol is viewed as a surrogate for apolipoprotein (Apo)B, an alternate end point of treatment. The present analysis of the previously reported Simvastatin plus Fenofibrate for Combined Hyperlipidemia (SAFARI) trial assessed the associations of non-HDL cholesterol and LDL cholesterol with ApoB levels in patients with combined hyperlipidemia treated with combination simvastatin (20 mg) and fenofibrate (160 mg) or simvastatin monotherapy (20 mg). The correlations of these factors were analyzed in the overall modified intent-to-treat population (n = 594) and in patient subgroups stratified by triglyceride (TG) tertiles. Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. The greatest reductions occurred with combination treatment. The baseline levels of non-HDL cholesterol and LDL cholesterol correlated highly with ApoB and were stronger in the lower TG tertiles than in the higher TG tertiles. After 12 weeks, the correlations had changed little with simvastatin monotherapy but had increased substantially with combination therapy and were most improved at high TG levels. In conclusion, these results suggest that both non-HDL cholesterol and ApoB provide similar information in relation to treatment response in patients with combined hyperlipidemia and hypertriglyceridemia, and that non-HDL cholesterol is a good indicator of ApoB-containing lipoproteins, supporting its recommended use as a secondary therapeutic target in these patients. SN - 1879-1913 UR - https://www.unboundmedicine.com/medline/citation/19660610/Correlation_of_non_high_density_lipoprotein_cholesterol_and_low_density_lipoprotein_cholesterol_with_apolipoprotein_B_during_simvastatin_+_fenofibrate_therapy_in_patients_with_combined_hyperlipidemia__a_subanalysis_of_the_SAFARI_trial__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(09)00921-7 DB - PRIME DP - Unbound Medicine ER -